Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler Curiel

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Cancer|June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.
Nature Communications|March 15, 2017
Suppressive IL-17A<sup>+</sup>Foxp3<sup>+</sup> and ex-Th17 IL-17A<sup>neg</sup>Foxp3<sup>+</sup> T<sub>reg</sub> cells are a source of tumour-associated T<sub>reg</sub> cellsStephanie Downs-Canner, Sara Berkey, Greg M Delgoffe, et al.
Oncotarget|June 28, 2017
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancerJinyou Liu, Suryavathi Viswanadhapalli, Lauren Garcia, et al.
The Journal of Experimental Medicine|April 12, 2006
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaIlona Kryczek, Linhua Zou, Paulo Rodriguez, et al.
Oncotarget|July 10, 2015
p53 and rapamycin are additiveBarbara Christy, Marco Demaria, Judith Campisi, et al.
Cancer Research|October 12, 2022
PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast CancerJuyeong Hong, Ji Hoon Lee, Zhao Zhang, et al.
Journal for Immunotherapy of Cancer|February 9, 2023
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effectsHaiyan Bai, Alvaro S Padron, Yilun Deng, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerMary L Disis, Sarah F Adams, Jyoti Bajpai, et al.
NPJ Precision Oncology|May 24, 2024
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosisBehnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P Pratap, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Cancer|June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.
Nature Communications|March 15, 2017
Suppressive IL-17A<sup>+</sup>Foxp3<sup>+</sup> and ex-Th17 IL-17A<sup>neg</sup>Foxp3<sup>+</sup> T<sub>reg</sub> cells are a source of tumour-associated T<sub>reg</sub> cellsStephanie Downs-Canner, Sara Berkey, Greg M Delgoffe, et al.
Oncotarget|June 28, 2017
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancerJinyou Liu, Suryavathi Viswanadhapalli, Lauren Garcia, et al.
The Journal of Experimental Medicine|April 12, 2006
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaIlona Kryczek, Linhua Zou, Paulo Rodriguez, et al.
Oncotarget|July 10, 2015
p53 and rapamycin are additiveBarbara Christy, Marco Demaria, Judith Campisi, et al.
Cancer Research|October 12, 2022
PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast CancerJuyeong Hong, Ji Hoon Lee, Zhao Zhang, et al.
Journal for Immunotherapy of Cancer|February 9, 2023
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effectsHaiyan Bai, Alvaro S Padron, Yilun Deng, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerMary L Disis, Sarah F Adams, Jyoti Bajpai, et al.
NPJ Precision Oncology|May 24, 2024
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosisBehnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P Pratap, et al.
Pageof 2